Health Care • Industrial Specialties
$4.40 ▲ +0.45
(+11.39%)
MKT CAP: $12.7M • VOL: 167.1K
52W L $3 52W H $23
ROARABLE / RQD
D • 50/100
PIOTROSKI
5 / 9
CLGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.4M | $515.0K | $11.0M |
| YoY Revenue Growth % | +360.4% | -95.3% | — |
| Gross Profit | $1.5M | -$1.1M | — |
| Gross Margin % | 64.8% | -50.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.5M | -$17.3M | -$7.5M |
| Operating Margin % | -80.0% | -80.0% | -68.5% |
| Net Income (GAAP) | -$11.5M | -$16.6M | -$7.0M |
| EBITDA (Normalized) | -$11.5M | -$16.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.4M | -$14.1M | -$2.8M |
| Capital Expenditures (CapEx) | $28.0K | $483.0K | — |
| Free Cash Flow (FCF) | -$9.4M | -$14.6M | -$2.8M |
| FCF Margin % | -80.0% | -80.0% | -25.2% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.6M | $11.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.1M | $13.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CLGN.